文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA PET评估177Lu-PSMA放射性配体治疗去势抵抗性前列腺癌的疗效反应

Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-12-19

该回顾性研究评估了68Ga-PSMA PET参数在转移性去势抵抗性前列腺癌(mCRPC)患者接受177Lu-PSMA-617放射性配体治疗(RLT)后疗效评估中的作用,并探讨与总生存期(OS)相关的因素。结果显示,PSMA PET上的总肿瘤体积(TTV)变化与PSA反应显著相关(p < 0.001),且TTV和PSA变化与OS相关,而SUVmean和RECIST评估则无此关联。结论提示TTV可能是RLT疗效评估的可靠参数,并可能克服RECIST在前列腺癌中的局限性。

要点

  • TTV变化与PSA反应显著相关(p < 0.001),而SUVmean和RECIST变化无显著关联。
  • TTV和PSA变化与OS相关(HR 1.001,95%CI 1-1.003,p=0.04;HR 1.004,95%CI 1.001-1.008,p=0.01)。
  • 治疗前CRP水平也与OS相关(HR 1.07,95%CI 1.009-1.14,p=0.02)。

核心结论

  • PSMA PET上的TTV似乎是mCRPC患者接受RLT后疗效评估的可靠参数,并可能克服RECIST在前列腺癌中的局限性。
  • TTV变化与OS显著相关。

研究设计与样本

  • 回顾性评估55例mCRPC患者中38例在RLT前后的PSMA PET参数(SUVmean和TTV)。
  • PSA检测和PSMA PET/CT(MRI)成像在RLT前8周内和RLT后6周内进行。
  • PSMA PET和CT(MRI)图像分别根据mPERCIST和RECIST1.1独立审查,并与PSA反应比较。
  • 采用单变量生存分析确定OS与RECIST评估及SUVmean、TTV、PSA、CRP、LDH、血红蛋白和ALP水平变化之间的关联。

主要发现

  • 治疗前PSMA PET/CT(MRI)时中位PSA水平为60.8 ng/ml(IQR 15.4,264.2 ng/ml)。
  • RLT后中位PSA水平下降44%,TTV下降45.1%,SUVmean下降25.8%,RECIST下降11.3%。
  • 18例(47.4%)患者出现PSA反应,12例(31.6%)疾病稳定,8例(21.1%)疾病进展。
  • TTV变化与PSA反应显著相关(p < 0.001),而SUVmean变化(p = 0.15)和RECIST评估(p = 0.58)无显著关联。
  • 中位随访17个月(IQR 8.0,24.2个月)后,11例(28.9%)患者死于前列腺癌。

关键数值与推荐

  • PSMA PET和CT(MRI)图像分别根据mPERCIST和RECIST1.1独立审查。
  • PSA反应、疾病稳定和疾病进展分别见于18例(47.4%)、12例(31.6%)和8例(21.1%)患者。
  • TTV变化与PSA反应显著相关(p < 0.001)。
  • TTV变化与OS相关(HR 1.001,95% CI 1-1.003,p = 0.04)。
  • PSA变化与OS相关(HR 1.004,95% CI 1.001-1.008,p = 0.01)。

临床怎么用

  • 在mCRPC患者接受177Lu-PSMA RLT后,可采用PSMA PET上的TTV变化作为疗效评估的参考参数。
  • TTV变化和PSA变化可用于提示OS相关风险,而SUVmean和RECIST评估在此场景下未显示与OS的关联。

局限性

  • 回顾性研究设计。
  • 仅评估了55例患者中的38例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The first aim of this study was to evaluate 68Ga-PSMAHBED-CC conjugate 11 positron emission tomography (PSMA PET) parameters for assessment of response to 177Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC). The second aim was to investigate factors associated with overall survival (OS). METHODS: We retrospectively assessed mean standardized uptake values (SUVmean) and total tumor volumes (TTV) on PSMA PET in 38 of 55 mCRPC patients before and after RLT. PSA testing and PSMA PET/CT(MRI) imaging were performed during the 8 weeks before and the 6 weeks after RLT. PSMA PET and CT(MRI) images were reviewed separately according to the modified PET Response Criteria in Solid Tumors (mPERCIST) and RECIST1.1. The results were compared with PSA responses. Associations between OS and the RECIST evaluation and changes in SUVmean, TTV, and PSA, CRP, LDH, hemoglobin and ALP levels were determined in a univariable survival analysis. RESULTS: The median PSA level at the time of pretherapy PSMA PET/CT(MRI) was 60.8 ng/ml (IQR 15.4, 264.2 ng/ml). After RLT the median PSA level decreased by 44%, TTV by 45.1%, SUVmean by 25.8% and RECIST by 11.3%. A PSA response was seen in 18 patients (47.4%), stable disease in 12 (31.6%) and progressive disease in 8 (21.1%). Contrary to the changes in SUVmean and the RECIST evaluation, the change in TTV was significantly associated with PSA response (p = 0.15, p = 0.58, and p < 0.001, respectively). After a median follow-up of 17 months (IQR 8.0, 24.2 months), 11 patients (28.9%) had died of their prostate cancer. The changes in both TTV and PSA levels were associated with OS (HR 1.001, 95% CI 1-1.003, p = 0.04, and HR 1.004, 95% CI 1.001-1.008, p = 0.01, respectively), while the changes in SUVmean and the RECIST evaluation were not. The pre-therapy CRP level was also associated with OS (HR 1.07, 95% CI 1.009-1.14, p = 0.02). CONCLUSION: TTV on PSMA PET seems to be a reliable parameter for response assessment in mCRPC patients undergoing RLT and might overcome the limitations of RECIST in prostate cancer. Furthermore, the change in TTV was significantly associated with OS in our cohort.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Grubmüller B, Senn D, Kramer G, et al. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 30569186. doi:10.1007/s00259-018-4236-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。